Updated on 30 July 2012
Following this, a panel was set up under the chairmanship of Mr Arun Maira, member, Planning Commission, at the behest of the cabinet committee on economic affairs, which suggested a status quo in the FDI policy for the sector while recommending oversight by the Competition Commission of India (CCI) on pricing and competition issues.
However, this recommendation was opposed by both the DIPP and the health ministry. Finally, a meeting called by Prime Minister Manmohan
Singh in October 2011 in order to resolve the differences came to a conclusion that while 100 percent FDI in greenfield investments through the automatic route will continue to be allowed, brownfield investments in Indian pharma companies will be routed through FIPB for six months (from October) and that CCI will then take over the job.